Phase 1 Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old at the time of signing the consent form.
- You have been diagnosed with one of the following conditions for at least 6 months: Lupus (SLE), Immune-Mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS), Myasthenia Gravis (MG), or Systemic Sclerosis (SSc).
- Your condition is still active or has come back despite being treated with standard therapies for at least 8 weeks, with your dose unchanged for more than 2 weeks, and you have tried at least two different immune-suppressing treatments.
- Your bone marrow, blood clotting, heart, lungs, liver, and kidneys are functioning adequately.
Who may not be able to join:
- You have tested positive for Hepatitis B, Hepatitis C, HIV, syphilis, CMV, or Epstein-Barr virus.
- You have an active infection that is not under control.
- You have received a live vaccine in the 4 weeks before signing the consent form.
- You have previously had a major organ transplant or a bone marrow/stem cell transplant.
- You have had a serious heart or cardiovascular problem in the past 6 months.
- You have had significant bleeding in the past 30 days, or you need to take blood-thinning medication long-term.
- You have not waited long enough after stopping your previous treatments before joining (confirm with trial site).
- You have previously been treated with CAR-T cell therapy or other genetically modified T cell therapies.
- You are currently pregnant or breastfeeding.
- You have severe disease or significant changes affecting your brain or nervous system.
- You have been diagnosed with cancer at any point in the 5 years before signing the consent form.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nan Shen, MD & PhD, Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University
Phone: +86-21-63260477
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Adverse Events [Safety and Tolerability]; The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.